CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-08-04). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 2236 · Search date 2026-08-04 · Methodology v0.6

Breastfeeding promotion and support,
does it really help with Reduced infant gastrointestinal infection through 12 months?

30-Second Summary
B
Evidence Grade B · 72 · Safety acceptable
A breastfeeding promotion and support program reduced infant gastrointestinal infection in the Belarus cluster trial
No major harm signal from promotion and support itself was established. Pain, mastitis, feeding difficulty, or infant growth concerns warrant qualified lactation and medical support.
What the
research shows
The grade is B. PROBIT cluster-randomized a breastfeeding promotion and support program at 31 maternity facilities, not breastfeeding itself. In the original cluster-adjusted analysis, infant gastrointestinal infection was 9.1% versus 13.2%, adjusted OR 0.60 (95% CI 0.40 to 0.91). Infant eczema also decreased, but asthma, allergy, obesity, and adiposity at age 6.5 years did not, so this must not be read as breastfeeding preventing many diseases.
What the
ads claim
The trial did not randomize breastfeeding itself. It randomized facility promotion and support, and claims must separate the outcomes that decreased from those that did not.
*

Useful facts when choosing a product

  • Exclusive breastfeeding at three months was 43.3% at intervention facilities versus 6.4% at usual-care facilities.
  • Gastrointestinal infection was 9.1% versus 13.2%, while respiratory infection was 39.2% versus 39.4%.
  • Verdict 1567 is C with 58 points and addresses six-month breastfeeding continuation; this verdict addresses the separate 12-month gastrointestinal-infection outcome.
Gap Measurement · Verdict 2236 · B 72
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

PROBIT cluster-randomized 31 Belarusian maternity hospitals and affiliated polyclinics, 16 versus 15. The 2001 report records 16,491 of 17,046 pairs completing 12-month follow-up, whereas the 2014 cohort profile records 16,492, a one-pair source difference. Gastrointestinal infection was 9.1% versus 13.2%, OR 0.60 (0.40 to 0.91), in analysis accounting for facility clustering. Infant eczema was positive, while asthma, allergy, obesity, and adiposity at age 6.5 years were all null. The trial ran in 1996-1997 and was registered much later.

02

Why this is classified as B (72)

A large cluster-randomized trial reduced infant gastrointestinal infection after cluster adjustment. Retrospective registration, lack of provider and assessor blinding, possible record-confirmation bias, and one-country one-period data give B with 72 points.

Counterpoint. Belarus had a centralized health system and routine six-to-seven-day postpartum stays. The result does not directly generalize to preterm or ill infants or families without an initial intention to breastfeed.

Rejudgment record. Cross-check applied — Cluster-adjusted gastrointestinal infection reduction after facility randomization, limited by retrospective registration, no provider or assessor blinding, possible record-confirmation bias, and one-country one-period data

Scoring profile behind this grade
EndpointHHard endpoint - actual events such as death
ReplicationR1Single confirmatory trial
IndependenceI2Decisive evidence is publicly or non-profit funded
Effect sizeE+Meets the clinically important threshold

The scoring table and the verdict agree (B).

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Reduced gastrointestinal infectionBThe cluster-adjusted OR was 0.60.
Reduced respiratory infectionDRates were 39.2% versus 39.4%, with no significant difference.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Study 1Cluster-randomized trial of 31 maternity facilities16,492Thrasher Research Fund, Health Canada, UNICEF, and WHO Regional Office for EuropeAt least one gastrointestinal infection through 12 months9.1% versus 13.2%; cluster-adjusted OR 0.60 (95% CI 0.40 to 0.91)Definitive large real-illness evidence
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-08-04).

Kramer MS, Chalmers B, Hodnett ED, et al. Promotion of Breastfeeding Intervention Trial (PROBIT): a randomized trial in the Republic of Belarus. JAMA. 2001;285(4):413-420. PMID: 11242425. DOI: 10.1001/jama.285.4.413.
checked
Patel R, Oken E, Bogdanovich N, et al. Cohort Profile: The Promotion of Breastfeeding Intervention Trial (PROBIT). Int J Epidemiol. 2014;43(3):679-690. PMID: 23471837. DOI: 10.1093/ije/dyt003.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-08-04 · Corrections: none

Cite this verdict

Breastfeeding promotion and support x reduced infant gastrointestinal infection Evidence Grade B card
[Chamgap] Breastfeeding promotion and support x reduced infant gastrointestinal infection — Evidence Grade B·72. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/immunity/breastfeeding-promotion-infant-gastrointestinal-infection/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.